Results from the fifth year of a long-term clinical study verify the disease
modifying effect of GRAZAX®. For the first time ever, it is documented that the
positive clinical effect of the tablet is sustained two years after completion
of treatment.

Today, ALK announces positive top-line results from the second and final
follow-up year in a long-term study (GT-08) with GRAZAX®, the company's grass
allergy immunotherapy tablet. The results verify that the disease-modifying
effect of GRAZAX® is sustained after completion of the recommended three-year
treatment regimen.

Two years after completed treatment, GRAZAX® reduced hay fever symptoms with
the same magnitude as in the previous year of the clinical study. The
significant reduction in hay fever symptoms was accompanied by less use of
symptomatic medications and consequently, a significant reduction in combined
symptom and medication score was obtained. Furthermore, the immunological
assessment continues to show a sustained, positive effect on the immune system
indicating a lasting tolerance to grass pollen.

The positive results were obtained despite a markedly lower grass pollen
exposure during 2009 compared to the previous pollen seasons in 2005-08.

In 2009, authorities in Europe approved GRAZAX® as a disease modifying allergy
treatment. The approval was based on the results of the first follow-up year in
the GT-08 study and the latest findings therefore reinforce the scientific and
clinical rationale of the product. GRAZAX® is the only registered tablet
treatment against grass pollen allergy with documented sustained effect after
completion of treatment.

ALK-Abelló A/S

Jens Bager

For further information please contact: Jens Bager, President and CEO,
tel. +45 4574 7576

Investor Relations: Per Plotnikof, tel +45 4574 7527, mobile +45 2261 2525
Press: Martin Barlebo, tlf. + 45 4574 7901, mobile + 45 2064 1143

fm-01-10-uk.pdf